By Fineline Cube The Anhui Provincial Healthcare Security Administration has formally invited other provinces to participate in a national biologics alliance volume-based procurement (VBP) specifically targeting monoclonal antibody drugs, with responses due by June 26, 2026.
Regulatory Framework & Timeline
| Item | Detail |
|---|---|
| Lead Authority | Anhui Provincial Healthcare Security Administration |
| Oversight Body | National Healthcare Security Administration (NHSA) |
| Initiative Start | Research and preparation began in 2024 |
| Response Deadline | June 26, 2026 |
| Procurement Type | National alliance volume-based procurement (VBP) |
| Target Category | Monoclonal antibody biologics |
Market Readiness Assessment
- Product Approvals: Over 100 monoclonal antibody products (including reference drugs and biosimilars) have received regulatory approval in China
- Clinical History: Earliest monoclonal antibodies introduced in China have accumulated more than 20 years of clinical usage data
- Supply Structure: Increasingly diversified manufacturer base with mature clinical protocols
- Consensus Building: Extensive industry consultation completed with broad stakeholder agreement
Current Drug List for Procurement
Following the August 1, 2025 information collection notice from the Anhui Provincial Medical Procurement Center, the current circulating procurement list includes seven monoclonal antibody drugs:
- Adalimumab
- Bevacizumab
- Denosumab
- Rituximab
- Trastuzumab
- Tocilizumab
- Infliximab
Note: Pertuzumab was included in earlier drafts but has been excluded from the final candidate list.
Strategic Implications
- Market Impact: This national alliance approach represents a significant evolution from provincial-level procurement toward standardized nationwide pricing for high-value biologics
- Cost Containment: Expected to generate substantial savings for China’s healthcare system while maintaining quality standards
- Industry Response: Manufacturers of the seven targeted monoclonal antibodies will need to prepare competitive pricing strategies ahead of the formal bidding process
- Implementation Timeline: Following the June 26 response deadline, formal procurement procedures are expected to commence in Q3 2026
Forward-Looking Statements
This brief contains forward-looking statements regarding China’s healthcare procurement policies and market implications. Actual implementation may vary based on provincial participation rates, industry feedback, and evolving regulatory guidance.-Fineline Info & Tech